Enlivex Therapeutics Gets Japan Patent Notice for Allocetra in Osteoarthritis Treatment
MT Newswires Live
2024-10-30
Enlivex Therapeutics (ENLV) said Wednesday it received a notice of allowance from the Japanese Patent Office for a patent application focused on the use of Allocetra in osteoarthritis patients.
The patent, which will secure the company's intellectual property rights in Japan until 2040, is expected to be officially issued by the end of Q2 2025, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。
热议股票
没有相关数据